A 58-year-old woman with symptomatic HFrEF (LVEF 30%) on ACE inhibitor and beta-blocker. What additional class provides morbidity and mortality benefi...

Question

A 58-year-old woman with symptomatic HFrEF (LVEF 30%) on ACE inhibitor and beta-blocker. What additional class provides morbidity and mortality benefit and is now a core pillar of therapy?

Accepted Answer

SGLT2 inhibitor

Answer

Ivabradine

Answer

Diltiazem

Answer

Nifedipine

Answer

Digoxin

"heart failure with reduced ef" MCQ (SBA): Heart Failure with reduced ejection fraction

A 58-year-old woman with symptomatic HFrEF (LVEF 30%) on ACE inhibitor and beta-blocker. What additional class provides morbidity and mortality benefit and is now a core pillar of therapy?